OWL devotes most of its R&D resources to the identification and validation of metabolic biomarkers associated to human diseases, as well as to the development of new diagnostic methods for their detection.
OWL participates regularly in R&D projects and clinical validations in collaboration with research centers, universities, hospitals and European companies involved in:
- Identifying biomarkers related to human diseases in order to develop new diagnostic methods and specific therapies.
- Developing technologies for the diagnosis and prognosis of complex diseases.
- Identifying metabolic expression profiles that characterize and allow for the prediction of candidate drugs, molecular mechanisms of action of drugs under development and for the evaluation of their potential toxicity.
Other human diseases such as multiple sclerosis, among others, represent the core of the research activity.
Among OWL´s customers are a number of Spanish, European and international pharmaceutical companies establishing collaborations with academic and industrial R&D centers to improve our metabolomic platform.